May 6th 2024
In an ambitious effort to address the ongoing uncertainty within the 340B Program space, 6 senators released a draft discussion bill earlier this year titled the SUSTAIN Act.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Significant Provider Relief Fund Updates: Expanded Eligibility and a Reporting Update
September 11th 2020The terms of participation in the phase 2 round of the Provider Relief Fund created an unintended exclusion for pharmacies that primarily serve Medicaid/Children’s Health Insurance Program patients.
Read More
Specialty Pharmacies Improve Patient Outcomes, Minimize Costs to Health Care System
September 9th 2020The goals of specialty pharmacy programs are to reduce or delay progression of the disease, improve patient outcomes, enhance patients’ quality of life, keep patients in the workforce longer, and decrease total health care costs.
Read More
Study: Medicare Beneficiaries Visit Pharmacies Much More Often than Primary Care Offices
August 3rd 2020The investigators noted that the shift toward value-based care has placed a greater emphasis on preventive care and chronic disease management services as delivered by multidisciplinary health care teams.
Read More
Pharmacists Express Concern Over Lack of Provider Status in Proposed Stimulus Package
July 28th 2020As legislators debate the next stimulus package, pharmacists are expressing dismay that the current language does not include designating pharmacists as providers under Medicare Part B for COVID-19 testing and immunization.
Read More
9 in 10 Americans Support Federal Intervention in Drug Prices in Response to COVID-19 Pandemic
June 19th 2020According to a new study by West Health and Gallup, 88% of US adults support the federal government directly negotiating the price of a COVID-19 treatment with a drug manufacturer upon its availability due to concerns regarding raised drug prices.
Read More